MCID: MXD026
MIFTS: 45

Mixed Glioma

Categories: Bone diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Mixed Glioma

MalaCards integrated aliases for Mixed Glioma:

Name: Mixed Glioma 12 54 15
Mixed Gliomas 12 70
Mixed Neuroglial Tumor 12
Glioma 70

Classifications:



External Ids:

Disease Ontology 12 DOID:5076
MeSH 44 D005910
NCIt 50 C3903
SNOMED-CT 67 443937008
UMLS 70 C0017638 C0259783

Summaries for Mixed Glioma

MalaCards based summary : Mixed Glioma, also known as mixed gliomas, is related to oligoastrocytoma and mixed oligodendroglioma-astrocytoma. An important gene associated with Mixed Glioma is GFAP (Glial Fibrillary Acidic Protein), and among its related pathways/superpathways are Glioma and MicroRNAs in cancer. The drugs Midazolam and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are Decreased sensitivity to paclitaxel and growth/size/body region

Related Diseases for Mixed Glioma

Diseases related to Mixed Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 234)
# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 32.1 MGMT IDH2 GFAP
2 mixed oligodendroglioma-astrocytoma 31.1 TP53 PTEN MGMT IDH2 IDH1 ATRX
3 glial tumor 30.6 PTEN OLIG2 EGFR
4 low grade glioma 30.4 MGMT IDH2 IDH1
5 anaplastic oligodendroglioma 30.3 OLIG2 MGMT IDH2
6 glioma susceptibility 1 30.3 TP53 IDH2 IDH1
7 juvenile pilocytic astrocytoma 29.9 NF1 IDH1
8 neuroma 29.8 NF1 MGMT GFAP
9 glioma 29.5 TP53 PTEN PDGFRA NF1 IDH2 IDH1
10 cellular ependymoma 29.5 NES MGMT GFAP EGFR
11 benign ependymoma 29.5 PTEN NF1 IDH1 GFAP
12 gliomatosis cerebri 28.8 TP53 PTEN NES IDH1 GFAP EGFR
13 rhabdomyosarcoma 28.2 TP53 PTEN PDGFRA NF1 NES MGMT
14 oligodendroglioma 28.1 TP53 PTEN PDGFRA OLIG2 NF1 MGMT
15 pilocytic astrocytoma 28.0 TP53 PTEN OLIG2 NF1 NES MGMT
16 high grade glioma 27.9 TP53 PTEN PDGFRA NF1 NES MGMT
17 glioblastoma 27.8 TP53 PTEN PDGFRA NF1 NES MGMT
18 malignant astrocytoma 27.8 TP53 PTEN PDGFRA OLIG2 NF1 NES
19 adult brainstem mixed glioma 11.3
20 anaplastic oligoastrocytoma 11.1
21 extraventricular neurocytoma 10.4 IDH1 GFAP
22 enchondroma 10.4 IDH2 IDH1
23 deep leiomyoma 10.4 PDGFRA GFAP
24 third ventricle chordoid glioma 10.4 OLIG2 GFAP
25 cytogenetically normal acute myeloid leukemia 10.4 IDH2 IDH1
26 angiocentric glioma 10.4 IDH1 GFAP
27 chordoid glioma 10.4 TP53 GFAP
28 intracranial chondrosarcoma 10.4 IDH2 IDH1
29 urethra transitional cell carcinoma 10.3 TP53 GFAP
30 periosteal chondrosarcoma 10.3 IDH2 IDH1
31 spinal cord astrocytoma 10.3 MGMT IDH1
32 frontal convexity meningioma 10.3 IDH1 GFAP
33 juxtacortical chondroma 10.3 IDH2 IDH1
34 laryngeal neuroendocrine tumor 10.3 TP53 IDH1
35 rhabdoid meningioma 10.3 OLIG2 GFAP
36 rhabdoid tumor predisposition syndrome 1 10.3 TP53 ATRX
37 childhood brain stem glioma 10.3 IDH1 ATRX
38 cerebrovascular benign neoplasm 10.3 TP53 GFAP
39 clear cell ependymoma 10.3 OLIG2 IDH1 GFAP
40 esophagus verrucous carcinoma 10.3 TP53 EGFR
41 conventional fibrosarcoma 10.3 TP53 PDGFRA
42 supratentorial primitive neuroectodermal tumor 10.3 OLIG2 IDH1 GFAP
43 adult brain stem glioma 10.3 MGMT IDH2 IDH1
44 pineal gland cancer 10.3 OLIG2 GFAP
45 esophageal basaloid squamous cell carcinoma 10.3 TP53 EGFR
46 protoplasmic astrocytoma 10.3 PHLDB1 IDH2
47 cervical adenosquamous carcinoma 10.3 PDGFRA EGFR
48 soft tissue sarcoma 10.2 TP53 EGFR
49 breast malignant phyllodes tumor 10.2 TP53 EGFR
50 supraglottis cancer 10.2 TP53 EGFR

Graphical network of the top 20 diseases related to Mixed Glioma:



Diseases related to Mixed Glioma

Symptoms & Phenotypes for Mixed Glioma

GenomeRNAi Phenotypes related to Mixed Glioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased sensitivity to paclitaxel GR00112-A-0 8.62 NF1 PTEN

MGI Mouse Phenotypes related to Mixed Glioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.21 ATRX EGFR FUBP1 GFAP IDH1 NF1
2 cardiovascular system MP:0005385 10.18 ATRX EGFR FUBP1 GFAP IDH2 NF1
3 mortality/aging MP:0010768 10.18 ATRX EGFR FUBP1 GFAP IDH1 MGMT
4 embryo MP:0005380 10.06 ATRX EGFR FUBP1 NF1 PDGFRA PTEN
5 muscle MP:0005369 9.97 EGFR GFAP NF1 OLIG2 PDGFRA PTEN
6 nervous system MP:0003631 9.96 ATRX EGFR FUBP1 GFAP MGMT NF1
7 neoplasm MP:0002006 9.92 EGFR IDH2 MGMT NF1 OLIG2 PDGFRA
8 respiratory system MP:0005388 9.61 EGFR FUBP1 IDH1 MGMT NF1 OLIG2
9 pigmentation MP:0001186 9.55 EGFR NF1 PDGFRA PTEN TP53
10 skeleton MP:0005390 9.28 EGFR IDH1 IDH2 NF1 OLIG2 PDGFRA

Drugs & Therapeutics for Mixed Glioma

Drugs for Mixed Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 489)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Lactitol Approved, Investigational Phase 4 585-86-4 157355
3
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
4
Phenobarbital Approved, Investigational Phase 4 50-06-6 4763
5
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
6
Trametinib Approved Phase 4 871700-17-3 11707110
7
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
8
Lacosamide Approved Phase 4 860352-01-8, 175481-36-4 219078
9
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
10
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
11
Topiramate Approved Phase 4 97240-79-4 5284627
12
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
13
Clobazam Approved, Illicit Phase 4 22316-47-8 2789
14
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
15
Rufinamide Approved Phase 4 106308-44-5 129228
16 Protein Kinase Inhibitors Phase 4
17 Calcium, Dietary Phase 4
18 Hypoglycemic Agents Phase 4
19 Analgesics, Non-Narcotic Phase 4
20 Analgesics Phase 4
21 Sodium Channel Blockers Phase 4
22 Diuretics, Potassium Sparing Phase 4
23 Hypnotics and Sedatives Phase 4
24 GABA Modulators Phase 4
25 Anti-Anxiety Agents Phase 4
26 Excitatory Amino Acid Antagonists Phase 4
27 calcium channel blockers Phase 4
28 Antipsychotic Agents Phase 4
29 GABA Agonists Phase 4
30
Calcium Nutraceutical Phase 4 7440-70-2 271
31
Dextroamphetamine Approved, Illicit Phase 3 51-64-9 5826
32
leucovorin Approved Phase 3 58-05-9 6006
33
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
34
Ifosfamide Approved Phase 3 3778-73-2 3690
35
Dalteparin Approved Phase 3 9005-49-6
36
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414
37
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
38
Trioxsalen Approved Phase 3 3902-71-4 5585
39
Somatostatin Approved, Investigational Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
40
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
41
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
42
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
43
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
44
Vinblastine Approved Phase 3 865-21-4 241903 13342
45
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
46
tannic acid Approved Phase 3 1401-55-4
47
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
48
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
49
Bevacizumab Approved, Investigational Phase 3 216974-75-3
50
Lomustine Approved, Investigational Phase 3 13010-47-4 3950

Interventional clinical trials:

(show top 50) (show all 1199)
# Name Status NCT ID Phase Drugs
1 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
2 Seizure Treatment IN Glioma (STING): Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
3 A Phase IV, Prospective, Open-Label, Parallel Study Evaluating the Effect of an Adjunctive Anti-Seizure Medication Using a Glutamatergic Modulator in Patients With Focal Epilepsy and High-Grade Glioma Recruiting NCT04650204 Phase 4 Phenobarbital, Phenytoin, Carbamazepine, Valproate, Gabapentin, Pregabalin, Lamotrigine, Topiramate, Leviteracetam, Lacosamide, Zonisamide, Clobazam, Oxcarbezepine, Rufinamide;Perampanel
4 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
5 Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
6 A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
7 Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study Unknown status NCT00256425 Phase 3
8 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
9 A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial Unknown status NCT02363075 Phase 3 Dexamfetamine sulphate;placebo
10 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
11 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
12 Barrow 5-ALA Intraoperative Confocal Evaluation Trial Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
13 Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma Unknown status NCT01878266 Phase 3
14 A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma Unknown status NCT02455245 Phase 3 Carboplatin;Vincristine
15 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
16 A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Unknown status NCT03633552 Phase 3 Temozolomide
17 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
18 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
19 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
20 A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE) Completed NCT00135876 Phase 3 dalteparin
21 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
22 PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
23 Clinical Study to Assess the Positive Predictive Value of NPC-07 Induced Tissue Fluorescence in Patients With Malignant Glioma (WHO Grades III/IV) Completed NCT01167322 Phase 3 NPC-07 for oral administration
24 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
25 DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial Completed NCT02678975 Phase 2, Phase 3 Disulfiram;Alkylating Agents
26 Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children. Completed NCT01635140 Phase 3
27 A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma Completed NCT01781468 Phase 3 armodafinil 150 mg;armodafinil 250 mg
28 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
29 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
30 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
31 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
32 EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
33 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
34 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
35 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
36 International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid
37 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
38 A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) Recruiting NCT03871257 Phase 3 Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
39 IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study Recruiting NCT03763422 Phase 3 Temozolomide
40 Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy - A Prospective Follow-up Study Recruiting NCT03534050 Phase 2, Phase 3
41 Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery Recruiting NCT04316039 Phase 2, Phase 3 Temozolomide
42 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation Recruiting NCT04164901 Phase 3 Vorasidenib;Matching Placebo
43 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
44 A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) Recruiting NCT04166409 Phase 3 Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
45 A Randomized Trial of Delayed Radiotherapy in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Oligodendroglial Tumors: the POLCA Trial. Recruiting NCT02444000 Phase 3 PCV chemotherapy alone;Radiotherapy+PCV chemotherapy
46 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
47 Interest of Fluorescein in Fluorescence-guided Resection of Gliomas: A Randomized Study Recruiting NCT03291977 Phase 3 Fluorescéine Sodique Faure
48 A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations Recruiting NCT04576117 Phase 3 Selumetinib Sulfate;Vinblastine Sulfate
49 3.0T High-field Intraoperative MRI Guided Extent of Resection in Cerebral Glioma Surgery: a Single Center Prospective Randomized Triple-blind Controlled Clinical Trial Active, not recruiting NCT01479686 Phase 3
50 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Active, not recruiting NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat

Search NIH Clinical Center for Mixed Glioma

Genetic Tests for Mixed Glioma

Anatomical Context for Mixed Glioma

MalaCards organs/tissues related to Mixed Glioma:

40
Brain, T Cells, Endothelial, Bone, Spinal Cord, Bone Marrow, Cortex

Publications for Mixed Glioma

Articles related to Mixed Glioma:

(show top 50) (show all 306)
# Title Authors PMID Year
1
A PDGFRA promoter polymorphism, which disrupts the binding of ZNF148, is associated with primitive neuroectodermal tumours and ependymomas. 54 61
15635072 2005
2
Tissue culture of human neurocytomas induces the expression of glial fibrilary acidic protein. 61 54
10451427 1998
3
Semiquantitative postembedding characterization of intermediate filaments in central nervous system lesions using immunoelectron microscopy. 61 54
9044656 1995
4
Trends in paediatric central nervous system tumour incidence by global region from 1988 to 2012. 61
33221912 2021
5
Radiotherapy in adult low-grade glioma: nationwide trends in treatment and outcomes. 61
32691365 2021
6
TEMOBIC: Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas: An ANOCEF Study. 61
33783067 2021
7
Therapeutic anti-glioma effect of the combined action of PCSK inhibitor with the anti-tumoral factors secreted by Poly (I:C)-stimulated macrophages. 61
33402730 2021
8
Patterns of care for pediatric patients with newly-diagnosed grade II gliomas. 61
33404712 2021
9
Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma. 61
31832215 2019
10
Synchronous identification of a dysembryoplastic neuroepithelial tumor (DNET) and an oligodendroglioma in a patient: A case report. 61
31262396 2019
11
Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study. 61
31136584 2019
12
Concurrent Versus Sequential Chemoradiation for Low-grade Gliomas Meeting RTOG 9802 Criteria. 61
30768441 2019
13
Glioblastoma in the setting of prior lower grade gliomas - insights from SEER database. 61
30279958 2018
14
Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach. 61
28958143 2018
15
[Adult intramedullary gliomas]. 61
28527519 2017
16
Malignant transformation of low-grade gliomas in patients undergoing adjuvant therapy. 61
27271289 2017
17
Clinicopathological features and microsurgical outcomes for giant pediatric intracranial tumor in 60 consecutive cases. 61
28180935 2017
18
The inhibiting activity of meadowsweet extract on neurocarcinogenesis induced transplacentally in rats by ethylnitrosourea. 61
27838807 2017
19
Proceedings of the 2016 National Toxicology Program Satellite Symposium. 61
27821709 2017
20
Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma. 61
28248126 2016
21
Unique case of oligoastrocytoma with recurrence and grade progression: Exhibiting differential expression of high mobility group-A1 and human telomerase reverse transcriptase. 61
27672647 2016
22
Morphological Patterns of Intracranial Lesions in a Tertiary Care Hospital in North Karnataka: A Clinicopathological and Immunohistochemical Study. 61
27656442 2016
23
Nogo-A inhibits the migration and invasion of human malignant glioma U87MG cells. 61
27109183 2016
24
Primary Spinal Oligoastrocytoma. 61
27092919 2016
25
Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification. 61
26115961 2016
26
The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. 61
26530262 2015
27
Updates in Molecular Pathology of Central Nervous System Gliomas in Adults. 61
26517249 2015
28
Treatment of anaplastic glioma. 61
25468227 2015
29
Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma"? 61
25359109 2015
30
Mixed Glioma (Oligoastrocytoma) in the brain of an African Hedgehog (Atelerix albiventris). 61
25172052 2014
31
[Low-grade gliomas in adults]. 61
25391745 2014
32
Polysomy of chromosomes 1 and 19: an underestimated prognostic factor in oligodendroglial tumors. 61
25007776 2014
33
Immunohistochemical evaluation of tissue factor, fibrin/fibrinogen and D-dimers in canine gliomas. 61
24745770 2014
34
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity. 61
23644658 2014
35
Trends in childhood brain tumor incidence, 1973-2009. 61
23925828 2013
36
Analyzing agreement patterns of intraoperative central nervous system lesion reporting according to type and grade. 61
24130410 2013
37
Immunohistochemical characterization of spontaneous and acrylonitrile-induced brain tumors in the rat. 61
22821367 2013
38
GFAP-positive neoplastic astrocytes in spontaneous oligodendrogliomas and mixed gliomas of rats. 61
23076037 2013
39
The Evangelismos hospital central nervous system tumor registry: Analysis of 1414 cases (1998-2009). 61
23533006 2013
40
Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system. 61
22890969 2012
41
Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event. 61
22844452 2012
42
Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers. 61
21889777 2011
43
The effect of WHO reclassification of necrotic anaplastic oligoastrocytomas on incidence and survival in glioblastoma. 61
21229290 2011
44
Glioma Indian scenario: Is there a human leucocyte antigen association? 61
22346237 2011
45
Pleomorphic xanthoastrocytoma and oligodendroglioma: collision of 2 morphologically and genetically distinct anaplastic components. 61
21214337 2011
46
Risk factors for oligodendroglial tumors: a pooled international study. 61
21149253 2011
47
Primary and metastatic intraaxial brain tumors: prospective comparison of multivoxel 2D chemical-shift imaging (CSI) proton MR spectroscopy, perfusion MRI, and histopathological findings in a group of 159 patients. 61
21165751 2011
48
[Beneficial outcomes of an interdisciplinary psychoeducative group intervention for patients with malignant gliomas and their relatives]. 61
21312092 2011
49
Coexistent pathology in chronic epilepsy patients with neoplasms. 61
20495542 2010
50
Persistent outpatient hyperglycemia is independently associated with survival, recurrence and malignant degeneration following surgery for hemispheric low grade gliomas. 61
19589201 2010

Variations for Mixed Glioma

Expression for Mixed Glioma

Search GEO for disease gene expression data for Mixed Glioma.

Pathways for Mixed Glioma

GO Terms for Mixed Glioma

Cellular components related to Mixed Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 PML body GO:0016605 8.8 TP53 PTEN ATRX

Biological processes related to Mixed Glioma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 response to oxidative stress GO:0006979 9.69 TP53 IDH1 EGFR
2 wound healing GO:0042060 9.61 PDGFRA NF1 EGFR
3 adrenal gland development GO:0030325 9.52 PDGFRA NF1
4 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.49 TP53 PTEN
5 2-oxoglutarate metabolic process GO:0006103 9.48 IDH2 IDH1
6 DNA damage response, signal transduction by p53 class mediator GO:0030330 9.46 TP53 ATRX
7 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.4 TP53 EGFR
8 NADP metabolic process GO:0006739 9.37 IDH2 IDH1
9 forebrain morphogenesis GO:0048853 9.32 PTEN NF1
10 negative regulation of neuroblast proliferation GO:0007406 9.26 TP53 NF1
11 response to organic cyclic compound GO:0014070 9.26 PTEN MGMT IDH1 EGFR
12 isocitrate metabolic process GO:0006102 9.16 IDH2 IDH1
13 glyoxylate cycle GO:0006097 8.62 IDH2 IDH1

Molecular functions related to Mixed Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet-derived growth factor receptor binding GO:0005161 9.16 PTEN PDGFRA
2 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH2 IDH1
3 isocitrate dehydrogenase activity GO:0004448 8.62 IDH2 IDH1

Sources for Mixed Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....